These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36808043)

  • 21. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
    J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
    [No Abstract]   [Full Text] [Related]  

  • 23. Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder.
    Kotzalidis GD; Lombardozzi G; Matrone M; Amici E; Perrini F; Cuomo I; De Filippis S
    Curr Neuropharmacol; 2021; 19(12):2296-2307. PubMed ID: 33441069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huang IC; Chang TS; Chen C; Sung JY
    Int J Neuropsychopharmacol; 2022 Dec; 25(12):969-978. PubMed ID: 35981958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis.
    Liguori C; Ferini-Strambi L; Izzi F; Mari L; Manfredi N; D'Elia A; Mercuri NB; Placidi F
    Br J Clin Pharmacol; 2019 Jan; 85(1):240-244. PubMed ID: 30328132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 27. Vortioxetine: A new alternative for the treatment of major depressive disorder.
    Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
    Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
    Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
    Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
    Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
    J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
    Dziwota E; Olajossy M
    Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
    McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
    Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
    J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.
    Vieta E; Florea I; Schmidt SN; Areberg J; Ettrup A
    Int Clin Psychopharmacol; 2019 Jul; 34(4):153-160. PubMed ID: 31094901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
    Cumbo E; Adair M; Åstrom DO; Christensen MC
    Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
    McIntyre RS; Lophaven S; Olsen CK
    Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
    Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
    Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.